Amarin SCOTUS Skinny Label Ruling

The US Supreme Court ruled in favor of Hikma regarding its generic version of Vascepa, clarifying the 'skinny label' pathway for generic drug manufacturers.

Key Takeaways

• 1.The US Supreme Court ruled unanimously in favor of Hikma, stating Amarin failed to show induced infringement of Vascepa patents via the 'skinny label' pathway.
• 2.The ruling clarifies the Section viii 'skinny label' pathway, likely increasing confidence for generic manufacturers to enter markets for off-patent indications.
• 3.Competitive dynamics for Amarin's Vascepa in the US remain unchanged as generics have already established significant market share.

Table of Contents

• Background
• Valuation and Risks
• Disclosure Appendix
• Ratings, coverage universe and related definitions